Therapeutic advances in oesophageal motility disorders.
D000322:Adrenergic Agonists / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004106:Dilatation; D004931:Esophageal Achalasia / Q000628:therapy; D004935:Esophageal Diseases / Q000628:therapy*; D004947:Esophagus / Q000502:physiology / Q000601:surgery; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D009566:Nitrates / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000627:therapeutic use; D010528:Peristalsis; D013035:Spasm; D013565:Sympatholytics / Q000627:therapeutic use
D000322:Adrenergic Agonists; D001549:Benzamides; D002121:Calcium Channel Blockers; D009566:Nitrates; D010276:Parasympatholytics; D010277:Parasympathomimetics; D013565:Sympatholytics; D006830:Hydralazine